Pediatric-cancer drug firm Day One Biopharmaceuticals files for IPO (Pending:DAWN)

Biotech firm Day One Biopharmaceuticals (Nasdaq:DAWN), which focuses on developing anti-cancer drugs for children, has filed for an IPO with a $100 million placeholder value.
Read More